IL4 and chronic rhinosinusitis with nasal polyps: According to the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), patients with severe CRSwNP and comorbid asthma or those whose blood eosinophil count is higher than 300 cells/mL are more likely to exhibit Type 2 inflammation and may, therefore, benefit from Type 2 biologic therapies, such as anti–IL-4/receptor alpha and anti–IL-5/receptor alpha molecules [73].